Rosen Law Firm announced on March 21 that it is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. following allegations that the company may have issued misleading business information to investors.
The investigation comes after Aldeyra received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for reproxalap, which led to a significant drop in the company’s stock price. The issue is important for investors who may be entitled to compensation if they purchased Aldeyra securities, as Rosen Law Firm is preparing a class action seeking recovery of investor losses.
According to the announcement, Aldeyra disclosed in a filing with the Securities and Exchange Commission that the FDA’s letter cited “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and noted “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.” The letter also stated concerns about inconsistent study results and questioned “the reliability and meaningfulness of the positive findings,” concluding that “the totality of evidence from the completed clinical trials does not support the effectiveness of the product.” Following this news, Aldeyra’s stock price fell by $2.99 per share, or 70.7%, closing at $1.24 per share on March 17.
Rosen Law Firm encourages affected investors to join the prospective class action by visiting their website or contacting Phillip Kim, Esq., for more information. The firm highlights its experience representing investors globally in securities class actions and shareholder derivative litigation.
PR Newswire operates in more than 170 countries and supports distribution in 40 languages, according to the official website. It aims to deliver global reach for press release distribution through its network of newsrooms and influencers as detailed on its official site. PR Newswire features expert editors with over a decade of experience providing around-the-clock support and SEO guidance according to its official website. The organization collaborates with over 500,000 media outlets and influencers worldwide as reported by its official site. Its services include press release distribution, AI-enhanced content tools, and social sharing features as outlined on its official website.
The outcome of this investigation could impact both current shareholders and future regulatory disclosures within biotechnology firms.
